{"prompt": "['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '7.', 'STUDY ASSESSMENTS AND PROCEDURES', '41', '7.1.', 'Time and Events Table', '42', '7.2.', 'Screening and Critical Baseline Assessments', '45', '7.2.1.', 'Pre-screening Visit', '45', '7.2.2.', 'Critical procedures performed at Screening (Visit 1)', '45', '7.2.2.1. Albuterol/Salbutamol Reversibility Assessment', '46', '7.2.3.', 'Critical procedures performed at first treatment Visit', '(Baseline V2)', '46', '7.3.', 'Efficacy Assessments', '47', '7.3.1.', 'HRQoL assessments: Completion of PRO questionnaires', 'in the Electronic Diary', '47', '7.3.1.1.', 'Self Administered Computerised Baseline', 'Dyspnea Index/Transitional Dyspnea Index', '(SAC BDI/TDI)', '47', '7.3.1.2.', 'SGRQ-C', '48', '7.3.1.3.', 'COPD Assessment Test (CAT)', '48', '7.3.1.4.', 'EXACT and the Evaluating Respiratory', 'Symptoms- COPD (E-RS: COPD)', '49', '7.3.1.5.', 'Subject Global Rating of COPD Severity and', 'Global Rating of Change in COPD', '49', '7.3.2.', 'Spirometry', '49', '7.3.3.', 'Inspiratory capacity (IC)', '50', '7.3.4.', 'COPD Exacerbation', '51', '7.3.5.', 'Clinically important deterioration (CID)', '51', '7.3.6.', 'Rescue albuterl/salbutamol use', '52', '7.3.7.', 'Physical activity monitor (study subset)', '52', '7.4.', 'Safety', '52', '7.4.1.', 'Adverse Events (AE) and Serious Adverse Events (SAEs)', '52', '7.4.1.1.', 'Time period and Frequency for collecting AE', 'and SAE information', '53', '7.4.1.2.', 'Method of Detecting AEs and SAEs', '53', '7.4.1.3.', 'Follow-up of AEs and SAEs', '53', '7.4.1.4.', 'Pneumonia Events', '54', '7.4.1.5.', 'Cardiovascular and Death Events', '54', '7.4.1.6.', 'Disease-Related Events and/or Disease-', 'Related Outcomes Not Qualifying as SAEs', '54', '7.4.1.7.', 'Regulatory Reporting Requirements for SAEs', '54', '7.4.1.8.', 'Additional Adverse Event (AE) Reporting', 'Requirements for Canadian investigators', '55', '7.4.2.', 'Pregnancy', '55', '7.4.3.', 'Medical Device Incidents (Including Malfunctions)', '55', '7.4.4.', 'Electrocardiogram (ECG)', '55', '7.5.', 'Genetics', '56', '8.', 'DATA MANAGEMENT', '56', '9.', 'STATISTICAL CONSIDERATIONS AND DATA ANALYSES', '56', '9.1.', 'Hypotheses', '56', '9.2.', 'Sample Size Considerations', '57', '9.2.1.', 'Sample Size Assumptions', '57', '9.2.2.', 'Sample Size Sensitivity', '57', '9.2.3.', 'Sample Size Re-estimation or Adjustment', '58', '6']['2016N277425_02', 'CONFIDENTIAL', '2018N377698_00', '201749', '9.3.', 'Data Analysis Considerations', '58', '9.3.1.', 'Analysis Populations', '58', '9.3.2.', 'Interim Analysis', '58', '9.4.', 'Key Elements of Analysis Plan', '58', '9.4.1.', 'Primary Analyses', '59', '9.4.2.', 'Other Analyses', '60', '10. STUDY GOVERNANCE CONSIDERATIONS', '60', '10.1. Posting of Information on Publicly Available Clinical Trial Registers', '60', '10.2.', 'Regulatory and Ethical Considerations, Including the Informed', 'Consent Process', '60', '10.3.', 'Quality Control (Study Monitoring)', '61', '10.4.', 'Quality Assurance', '61', '10.5.', 'Study and Site Closure', '62', '10.6.', 'Records Retention', '62', '10.7.', 'Provision of Study Results to Investigators, Posting of Information', 'on Publically Available Clinical Trials Registers and Publication', '63', '11. REFERENCES', '64', '12. APPENDICES', '67', '12.1. Appendix 1: Abbreviations and Trademarks', '67', '12.2.', 'Appendix 2: Liver Safety Required Actions and Follow up', 'Assessments', '69', '12.3. Appendix 3: Genetic Research', '71', '12.4. Appendix 4: Definition of and Procedures for Recording, Evaluating,', 'Follow-Up and Reporting of Adverse Events', '74', '12.4.1.', 'Definition of Adverse Events', '74', '12.4.2.', 'Definition of Serious Adverse Events', '75', '12.4.3.', 'Definition of Cardiovascular Events', '76', '12.4.4.', 'Recording of AEs and SAEs', '77', '12.4.5.', 'Evaluating AEs and SAEs', '77', '12.4.6.', 'Reporting of SAEs to GSK', '79', '12.5. Appendix 5: COPD Exacerbation Identification, Categorization and', 'Treatment Guidelines', '80', '12.5.1.', 'Guidelines for Identifying COPD Exacerbations', '80', '12.5.2.', 'COPD Exacerbation Severity', '81', '12.5.3.', 'Treatment of COPD Exacerbations', '81', '12.5.4.', 'Guidelines for Treatment with Corticosteroids', '81', '12.5.5.', 'Guidelines for Treatment with Antibiotics', '82', '12.5.6.', 'Onset and Resolution of COPD Exacerbations', '82', '12.5.7.', 'Guideline for assessing multiple mild exacerbations', '82', '12.5.8.', 'Guideline for assessing exacerbations that increase in', 'severity', '82', '12.6.', 'Appendix 6: Definition of and Procedures for Documenting Medical', 'Device Incidents', '83', '12.6.1.', 'Definitions of a Medical Device Incident', '83', '12.6.2. Documenting Medical Device Incidents', '84', '12.7.', 'Appendix 7: Modified List of Highly Effective Methods for Avoiding', 'Pregnancy in FRP and Collection of Pregnancy Information', '85', '12.7.1. Modified List of Highly Effective Methods for Avoiding', 'Pregnancy in Females of Reproductive Potential (FRP)', '85', '7']\n\n###\n\n", "completion": "END"}